K. C. Waterman, and R. C. Adami. Accelerated aging: prediction of chemical stability of pharmaceuticals. Int. J. Pharm.
F. J. Urban, V. J. Jasys, J. W. Raggon, R. A. Buzon, P. D. Hill, J. F. Eggler, and J. D. Weaver. Novel synthesis of 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methylethyl)furan-2-sulfonyl]urea, an antiinflammatory agent. Synth. Comm.
B. Li, B. Andresen, M. F. Brown, R. A. Buzon, C. K.-F. Chiu, M. Couturier, E. Dias, F. J. Urban, V. J. Jasys, J. C. Kath, W. Kissel, T. Le, Z. J. Li, J. Negri, C. S. Poss, J. Tucker, D. Whritenour, and K. Zandi. Process development of CP-481715, a novel CCR1 antagonist. Org. Proc. Res. Dev.
D. T. Friesen, M. J. Gumkowski, R. J. Ketner, D. A. Lorenz, J. A. S. Nightingale, R. M. Shanker, and J. B. West. Pharmaceutical compositions of dispersions of drugs and neutral polymers. Int. Patent Appl. WO 2003000235A1 (2003) p. 210.
M. M Hayward. Preparation of [(2-piperazinyl-2-oxoethoxy)phenyl]alkanesulfonic acids and analogs as CCR1 receptor antagonists for treatment of inflammation and immune disorders. Int. Patent Appl. WO2002102787A2, p. 44 (2002).
M. F. Brown, A. S. Gaweco, R. P. Gladue, and M. M. Hayward. Preparation of piperazine sulfonic acid derivatives as chemokine receptors CCR1 antagonists for the treatment of fibrosis, Alzheimer disease and other disorders Int. Patent Appl. WO2004039377A1, p. 56 (2004).
U. Kaufmann. Preparation of piperazine derivatives as CCR1 antagonists for the treatment of endometriosis. Int. Patent Appl. WO2005079769A2 pp. 291 (2005).
K. M. Alsante, P. Boutros, M. A. Couturier, R. C. Friedmann, J. W. Harwood, G. J. Horan, A. J. Jensen, Q. Liu, L. L. Lohr, R. Morris, J. W. Raggon, G. L. Reid, D. P. Santafianos, T. R. Sharp, J. L. Tucker, and G. E. Wilcox. Pharmaceutical impurity identification: A case study using a multidisciplinary approach. J. Pharm.Sci.
T. Vlase, G. Vlase, and N. Doca. Thermal stability of food additives of glutamate and benzoate type. J. Therm. Anal. Calor.
G. T. Long, S. Vyazovkin, N. Gamble, and C. A. Wight. Hard to swallow dry: kinetics and mechanism of the anhydrous thermal decomposition of acetylsalicylic acid. J. Pharm. Sci.
S. Yoshioka and V. J. Stella. Stability of Drugs and Dosage Forms, Plenum, New York, 2000, pp. 108–113.
T. Hladon, B. Cwiertnia. The effect of humidity on the stability of diclofenac sodium in inclusion complex with ß-cyclodextrin in the solid state. Pharmazie
D. Genton and U. W. Kesselring. Effect of temperature and relative humidity on nitrazepam stability in solid state. J. Pharm. Sci.
M. Zajac. Stability of crystalline mecilliname sodium salt in the solid phase. Acta Pol. Pharm.
M. C. Lai, M. J. Hageman, R. L. Schowen, R. T. Borchardt, and E. M. Topp. Chemical stability of peptides in polymers. 1. Effect of water on peptide deamidation in poly(vinyl alcohol) and poly(vinyl pyrrolidone) matrixes. J. Pharm. Sci.
L. N. Bell and M. J. Hageman. Differentiating between the effects of water activity and glass transition dependent mobility on a solid state chemical reaction: aspartame degradation. J. Agric. Food Chem.
Z. Plotkowiak. The effect of chemical character of certain penicillins on the stability of the ß-lactam group in their molecules. Pharmazie
E. Pawelczyk, Z. Plotkowiak, and M. Helska. Kinetics of thermal decomposition of talampicillin hydrochloride in the solid state. Pharmazie
F.Y. Tripet and U.W. Kesselring. Etude de stabilité de l-acide folique à l’état solide en function de la température et de l’humidité. Pharm Acta Helv.
R. G. Strickley and B. D. Anderson. Solid-state stability of human insulin II. Effect of water on reactive intermediate partitioning in lyophiles from pH 2–5 solutions: stabilization against covalent dimmer formation. J. Pharm. Sci.